@article {7947,
	title = {Primary gastrointestinal non-Hodgkin{\textquoteright}s lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)},
	journal = {Leukemia and Lymphoma},
	volume = {47},
	year = {2006},
	note = {Cited By :64Export Date: 21 February 2017},
	month = {2006},
	pages = {2140 - 2146},
	abstract = {The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin{\textquoteright}s lymphoma (GI NHL). Among 810 patients with NHL, 128 cases (15.8\%) were diagnosed as primary GI tract NHL. There were 79 males and 49 females with median age of 62 years. The most common primary site was the stomach (68\%). Overall, 67.2\% of the patients were in stages I-II, and 32.8\% in stages III-IV. Simultaneous involvement of the GI tract and other extranodal sites was observed in 26 patients (20\%). Extranodal marginal zone B-cell lymphoma (MZBL) (i.e., low-grade lymphoma of mucosa-associated lymphoid tissue type) accounted for 48.4\% of lymphomas. Aggressive lymphomas (diffuse large B-cell lymphoma [DLBL]) accounted for 44.5\%. Eighty-three patients (67.5\%) achieved complete response (CR), either by surgery (43/ 43 patients, 17 with DLBL and 25 with MZBL) or by primary chemotherapy (40/64 patients, 22 with DLBL and 17 with MZBL). Sixty-two patients remain in CR; 33/43 after surgical resection (13/17 with DLBL and 20/25 patients with MZBL), and 29/40 after only chemotherapy (18/22 with DLBL and 10/17 with MZBL). The major prognostic factor for outcome in the present study was the stage of the disease. Patients with localized lymphoma (stage I and II) had significantly longer DFS and OS (DFS and OS at 3-year: 83\% and 87\%, respectively) than patients with extended disease (stage III and IV) (DFS and OS at 3-year: 46\% and 60\%, respectively) (P < 0.0001). The International Prognostic Index (IPI) for patients with aggressive lymphomas was prognostic only for DFS (79\% for low-risk patients [IPI score 0-1] vs 49\% for higher risk groups [IPI score 0-1] at 3-year, P = 0.0131).},
	keywords = {Extranodal, Intestinal, Lymphoma, Stomach},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750442200\&doi=10.1080\%2f10428190600709226\&partnerID=40\&md5=868449a0f6844ccd67f7f3517281a2c9},
	author = {Papaxoinis, G. and Papageorgiou, S. and Rontogianni, D. and Kaloutsi, V. and Fountzilas, G. and N. Pavlidis and Dimopoulos, M. and Tsatalas, C. and Xiros, N. and Economopoulos, T.}
}
